Project Grant R01AR083018

Award Date 4/19/24
Completion Date 2/28/29
Dollars Obligated $1.5M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop optical redox imaging (ORI) as a diagnostic and evaluative tool for osteoarthritis (OA) and other cartilage diseases. The $359,207 award, valid from September 1, 2024 to August 31, 2028, will be used to: 1) develop a stress test to diagnose cartilage disease based on changes in ORI...
This federal Project Grant award of $1,288,152 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a transformative high-throughput screening approach to identify nanoparticles (NPs) that can target specific cell types in osteoarthritis (OA) joints. The project, titled "Exploring Nano-Bio Interactions for Cell-Specific Targeting of...
This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop computational tools to accurately predict and interpret different patterns of knee pain in patients with osteoarthritis. The $348,680 award, with a period of performance from Sep 26, 2024 to Aug 31, 2026, will enable researchers at the University of Arizona to: 1) Adapt a...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant (CFDA 93.846) to the University of Massachusetts Medical School (UMass Medical) to create a comprehensive biomedical knowledgebase for the Osteoarthritis Initiative (OAI) cohort study. The goal is to promote and facilitate the use of the OAI's extensive clinical data, medical images, genetics, and biospecimens to accelerate osteoarthritis research. Key products and services...
This $426,250 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to the Regents of the University of Minnesota aims to develop an exosome-based therapy for the treatment of osteoarthritis (OA). The project will leverage the immunoregulatory mechanisms present during fetal development to identify multi-tissue organoid-derived exosomes with anti-inflammatory and chondrocyte proliferation potential. Key activities include in vitro studies using human PBMCs to...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to define the systemic mechanisms by which adipose (fat) tissue communicates with the knee joint to drive the development of osteoarthritis (OA). The $1,476,001 award to the Regents of the University of California, San Francisco will fund a comprehensive investigation of three potential interorgan crosstalk pathways: signaling through...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $711,161 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Northwestern University. The grant will fund research to define and validate guidelines for interpreting commonly used patient-reported outcome measures (PROMs) for pain and physical function in patients with advanced knee osteoarthritis (OA) receiving medical, rehabilitation, or surgical treatment. The...
This three-year, $906,000 project grant from the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases will fund research into obesity-promoting protein malonylation and its role in chondrocyte metabolic dysfunction and osteoarthritis development. Specifically, the grantee - Ohio University - will investigate how obesity accelerates osteoarthritis through "carbon stress," which causes metabolic byproducts to accumulate in cartilage...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...

NOVEL NON-CONTRAST MRI TO ASSESS SYNOVITIS IN OSTEOARTHRITIS - PROJECT SUMMARY OSTEOARTHRITIS (OA) IS A LEADING CAUSE OF DISABILITY THAT REDUCES PRODUCTIVITY AND QUALITY OF LIFE AT TREMENDOUS ECONOMIC COST. DESPITES ITS PREVALENCE AND COST, THERE IS NO THERAPY THAT PREVENTS OR CURES OA. SYNOVIAL INFLAMMATION (SYNOVITIS), HAS BEEN LINKED WITH PAIN, DISEASE SEVERITY AND PROGRESSION OF KNEE OA AND IS INCREASINGLY RECOGNIZED FOR ITS ROLE IN THE ONSET AND PATHOGENESIS OF OA. HOWEVER, STUDIES OF SYNOVITIS IN OA HAVE BEEN LIMITED BY A LACK OF NON-INVASIVE AND NON-CONTRAST METHODS TO EVALUATE ITS ROLE IN WHOLE-JOINT DISEASE, PARTICULARLY IN EARLY PROGRESSION AND IN RESPONSE TO TREATMENT. MRI HAS BECOME THE HALLMARK FOR IMAGING OF OA YET CONVENTIONAL MRI STRUGGLES TO DIFFERENTIATE SYNOVIAL HYPERTROPHY FROM ADJACENT FLUID, THUS MAKING IT DIFFICULT TO IDENTIFY AND CHARACTERIZE SYNOVITIS. CONTRAST-ENHANCED (CE) MRI, FOLLOWING INTRAVENOUS INJECTION OF A GADOLINIUM- BASED CONTRAST-AGENT, PROVIDES CONTRAST TO THE HIGHLY VASCULARIZED SYNOVIUM AND IS THE CURRENT REFERENCE STANDARD FOR IMAGING SYNOVITIS15. HOWEVER, ADDED TIME, COST, AND CONTRAINDICATIONS IN PATIENTS WITH RENAL DYSFUNCTION, HAVE LIMITED USE OF CE-MRI IN OA. THERE REMAINS A CRITICAL NEED FOR NEW, VALIDATED, AND TRANSLATABLE IMAGING TOOLS TO BETTER EVALUATE THE ROLE OF SYNOVITIS IN OA PATHOGENESIS AND RESPONSE TO TREATMENT. MRI HAS SHOWN PROMISE TO USE DIFFERENCES IN RELAXATION AND DIFFUSION PROPERTIES BETWEEN SYNOVIUM AND JOINT FLUID TO NOT ONLY PROVIDE CONTRAST TO SYNOVIUM BUT TO ALSO EVALUATE INFLAMMATORY ACTIVITY WITHOUT CONTRAST INJECTION. HOWEVER, TECHNICAL CHALLENGES REMAIN FOR DETECTION OF LOW-GRADE HYPERTROPHY, AS WELL AS ISOLATING SYNOVIUM AND REDUCING DISTORTIONS IN DIFFUSION MRI. FURTHER, VALIDATION STUDIES ARE NECESSARY TO UNDERSTAND THESE NC MRI MARKERS AND EVALUATE THEIR UTILITY AS A TARGET TO PREDICT AND MONITOR TREATMENT RESPONSE AND OA PROGRESSION THIS PROJECT AIMS TO DEVELOP AND OPTIMIZE NON-CONTRAST MRI METHODS TO ASSESS SYNOVITIS IN KNEE OA, TO VALIDATE THESE METHODS AGAINST HISTOLOGY, AND TO EVALUATE THEIR ABILITY TO PREDICT WHOLE JOINT DISEASE PROGRESSION AND AS A TARGET AND MONITOR OF TREATMENT RESPONSE. OUR SPECIFIC AIMS ARE (1A) TO DEVELOP NON-CONTRAST MRI METHODS FOR ASSESSING SYNOVIAL HYPERTROPHY AND INFLAMMATION ACROSS BOTH KNEES; (1B) TO VALIDATE THE SENSITIVITY AND SPECIFICITY OF THESE APPROACHES AGAINST GOLD STANDARD HISTOLOGIC MEASURES OF HYPERTROPHY AND INFLAMMATORY MARKERS AND REFERENCE CONTRAST-BASED IMAGING METRICS; AND [2] TO EVALUATE THE POTENTIAL OF NC-MRI SYNOVITIS MEASURES TO PREDICT AND CHARACTERIZE TREATMENT RESPONSE TO ANTI-INFLAMMATORY OA TREATMENT (2A) AS WELL AS TO PREDICT OA PROGRESSION AND EVALUATE WHOLE-JOINT SPATIAL TISSUE RELATIONSHIPS (2B). THE SIGNIFICANCE OF THIS WORK IS NEW NON-INVASIVE AND NON-CONTRAST TOOLS THAT GREATLY EXPAND THE ABILITY TO EVALUATE SYNOVITIS IN ALL ASPECTS OF OA: EARLY DIAGNOSIS, PATHOGENESIS AND PROGRESSION, AS WELL AS ENDOTYPE EVALUATION AND TREATMENT MONITORING. THE INNOVATION OF THIS PROJECT IS THE DEVELOPMENT OF NOVEL NC METHODS TO ASSESS SYNOVITIS IN OA AND ITS ROLE IN OA PATHOGENESIS AND RESPONSE TO TREATMENT. OUR INVESTIGATIVE TEAM INCLUDES EXPERTS IN NOVEL IMAGING TECHNIQUES, CLINICAL AND RESEARCH STUDIES OF OA, AND MUSCULOSKELETAL CLINICIANS.

Posted 4/18/24, 12:00 AM